Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination Against Botulinum C and D Neurotoxins.

Snow DM, Riling K, Kimbler A, Espinoza Y, Wong D, Pham K, Martinez Z, Kraus CN, Conrad F, Garcia-Rodriguez C, Cobb RR, Marks JD, Tomic MT.

Antimicrob Agents Chemother. 2019 Oct 7. pii: AAC.01270-19. doi: 10.1128/AAC.01270-19. [Epub ahead of print]

2.

Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity.

Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, Kumar S, Lulo J, Paragas V, Wong C, Suchy J, Grabow S, Dugast AS, Zhang H, Depis F, Feau S, Jakubowski A, Qiao W, Craig G, Razlog M, Qiu J, Zhou Y, Marks JD, Croft M, Drummond DC, Raue A.

Sci Transl Med. 2019 Oct 2;11(512). pii: eaax0720. doi: 10.1126/scitranslmed.aax0720.

PMID:
31578241
3.

Tailoring Biomimetic Phosphorylcholine-Containing Block Copolymers as Membrane-Targeting Cellular Rescue Agents.

Wang JY, Chen W, Nagao M, Shelat P, Hammer BAG, Tietjen GT, Cao KD, Henderson JM, He L, Lin B, Akgun B, Meron M, Qian S, Ward S, Marks JD, Emrick T, Lee KYC.

Biomacromolecules. 2019 Sep 9;20(9):3385-3391. doi: 10.1021/acs.biomac.9b00621. Epub 2019 Aug 19.

PMID:
31424203
4.

Characterization of the 18 kDa translocator protein (TSPO) expression in post-mortem normal and Alzheimer's disease brains.

Gui Y, Marks JD, Das S, Hyman BT, Serrano-Pozo A.

Brain Pathol. 2019 Jul 5. doi: 10.1111/bpa.12763. [Epub ahead of print]

PMID:
31276244
5.

Approaches to Noninvasive Respiratory Support in Preterm Infants: From CPAP to NAVA.

Hussain WA, Marks JD.

Neoreviews. 2019 Apr;20(4):e213-e221. doi: 10.1542/neo.20-4-e213.

PMID:
31261062
6.

Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats.

Espinoza Y, Wong D, Ahene A, Der K, Martinez Z, Pham J, Cobb RR, Farr-Jones S, Marks JD, Tomic MT.

Toxins (Basel). 2019 Jun 17;11(6). pii: E345. doi: 10.3390/toxins11060345.

7.

Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model.

Tomic MT, Espinoza Y, Martinez Z, Pham K, Cobb RR, Snow DM, Earnhart CG, Pals T, Syar ES, Niemuth N, Kobs DJ, Farr-Jones S, Marks JD.

Toxins (Basel). 2019 Apr 6;11(4). pii: E208. doi: 10.3390/toxins11040208.

8.

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.

Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC.

Nat Biomed Eng. 2019 Apr;3(4):264-280. doi: 10.1038/s41551-019-0385-4. Epub 2019 Apr 5.

PMID:
30952988
9.

Botulinum Neurotoxins (BoNTs)-Antibody and Vaccine.

Lou J, Marks JD.

Toxins (Basel). 2018 Nov 26;10(12). pii: E495. doi: 10.3390/toxins10120495.

10.

Toxic Protein Spread in Neurodegeneration: Reality versus Fantasy.

Kara E, Marks JD, Aguzzi A.

Trends Mol Med. 2018 Dec;24(12):1007-1020. doi: 10.1016/j.molmed.2018.09.004. Epub 2018 Nov 12. Review.

PMID:
30442495
11.

Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells.

Takasaka N, Seed RI, Cormier A, Bondesson AJ, Lou J, Elattma A, Ito S, Yanagisawa H, Hashimoto M, Ma R, Levine MD, Publicover J, Potts R, Jespersen JM, Campbell MG, Conrad F, Marks JD, Cheng Y, Baron JL, Nishimura SL.

JCI Insight. 2018 Oct 18;3(20). pii: 122591. doi: 10.1172/jci.insight.122591.

12.

A flow cytometry-based in vitro assay reveals that formation of apolipoprotein E (ApoE)-amyloid beta complexes depends on ApoE isoform and cell type.

Kara E, Marks JD, Roe AD, Commins C, Fan Z, Calvo-Rodriguez M, Wegmann S, Hudry E, Hyman BT.

J Biol Chem. 2018 Aug 24;293(34):13247-13256. doi: 10.1074/jbc.RA117.001388. Epub 2018 Jun 27.

13.

Antibody engineering to improve manufacturability.

Wijesuriya SD, Pongo E, Tomic M, Zhang F, Garcia-Rodriquez C, Conrad F, Farr-Jones S, Marks JD, Horwitz AH.

Protein Expr Purif. 2018 Sep;149:75-83. doi: 10.1016/j.pep.2018.04.003. Epub 2018 Apr 12.

PMID:
29655788
14.

Poloxamer 188 decreases membrane toxicity of mutant SOD1 and ameliorates pathology observed in SOD1 mouse model for ALS.

Riehm JJ, Wang L, Ghadge G, Teng M, Correa AM, Marks JD, Roos RP, Allen MJ.

Neurobiol Dis. 2018 Jul;115:115-126. doi: 10.1016/j.nbd.2018.03.014. Epub 2018 Apr 5.

15.

A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes.

Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD.

Toxins (Basel). 2018 Mar 1;10(3). pii: E105. doi: 10.3390/toxins10030105.

16.

A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.

Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD.

Toxins (Basel). 2018 Feb 15;10(2). pii: E84. doi: 10.3390/toxins10020084.

17.

Discovery of internalizing antibodies to basal breast cancer cells.

Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD.

Protein Eng Des Sel. 2018 Jan 1;31(1):17-28. doi: 10.1093/protein/gzx063.

18.

Noninvasive Ventilation in the Premature Newborn - Is Less Always More?

Schreiber MD, Marks JD.

N Engl J Med. 2017 Jul 27;377(4):386-388. doi: 10.1056/NEJMe1707439. No abstract available.

PMID:
28745997
19.

Isoform- and cell type-specific structure of apolipoprotein E lipoparticles as revealed by a novel Forster resonance energy transfer assay.

Kara E, Marks JD, Fan Z, Klickstein JA, Roe AD, Krogh KA, Wegmann S, Maesako M, Luo CC, Mylvaganam R, Berezovska O, Hudry E, Hyman BT.

J Biol Chem. 2017 Sep 8;292(36):14720-14729. doi: 10.1074/jbc.M117.784264. Epub 2017 Jul 6.

20.

Mitochondrial mechanisms of neuronal rescue by F-68, a hydrophilic Pluronic block co-polymer, following acute substrate deprivation.

Wang JC, Bindokas VP, Skinner M, Emrick T, Marks JD.

Neurochem Int. 2017 Oct;109:126-140. doi: 10.1016/j.neuint.2017.04.007. Epub 2017 Apr 19. Review.

21.

A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes.

Fan Y, Garcia-Rodriguez C, Lou J, Wen W, Conrad F, Zhai W, Smith TJ, Smith LA, Marks JD.

PLoS One. 2017 Mar 21;12(3):e0174187. doi: 10.1371/journal.pone.0174187. eCollection 2017.

22.

SUMOylation of NaV1.2 channels mediates the early response to acute hypoxia in central neurons.

Plant LD, Marks JD, Goldstein SA.

Elife. 2016 Dec 28;5. pii: e20054. doi: 10.7554/eLife.20054.

23.

Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting.

Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, Rennard R, Xu L, Schoerberl B, Marks JD, Drummond DC, Lugovskoy AA.

MAbs. 2017 Jan;9(1):58-67. doi: 10.1080/19420862.2016.1259047. Epub 2016 Nov 17.

24.

White Matter Injury and General Movements in High-Risk Preterm Infants.

Peyton C, Yang E, Msall ME, Adde L, Støen R, Fjørtoft T, Bos AF, Einspieler C, Zhou Y, Schreiber MD, Marks JD, Drobyshevsky A.

AJNR Am J Neuroradiol. 2017 Jan;38(1):162-169. doi: 10.3174/ajnr.A4955. Epub 2016 Oct 27.

25.

Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids.

Chlenski A, Dobratic M, Salwen HR, Applebaum M, Guerrero LJ, Miller R, DeWane G, Solomaha E, Marks JD, Cohn SL.

Oncotarget. 2016 Nov 22;7(47):77696-77706. doi: 10.18632/oncotarget.12773.

26.

Network burst activity in hippocampal neuronal cultures: the role of synaptic and intrinsic currents.

Suresh J, Radojicic M, Pesce LL, Bhansali A, Wang J, Tryba AK, Marks JD, van Drongelen W.

J Neurophysiol. 2016 Jun 1;115(6):3073-89. doi: 10.1152/jn.00995.2015. Epub 2016 Mar 16.

27.

Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.

Fan Y, Barash JR, Lou J, Conrad F, Marks JD, Arnon SS.

J Infect Dis. 2016 May 15;213(10):1606-14. doi: 10.1093/infdis/jiv770. Epub 2016 Mar 1.

28.

Checklists and Other Cognitive Aids For Emergency And Routine Anesthesia Care-A Survey on the Perception of Anesthesia Providers From a Large Academic US Institution.

Krombach JW, Edwards WA, Marks JD, Radke OC.

Anesth Pain Med. 2015 Aug 22;5(4):e26300. doi: 10.5812/aamp.26300v2. eCollection 2015 Aug.

29.

Development and Implementation of Checklists for Routine Anesthesia Care: A Proposal for Improving Patient Safety.

Krombach JW, Marks JD, Dubowitz G, Radke OC.

Anesth Analg. 2015 Oct;121(4):1097-103. doi: 10.1213/ANE.0000000000000923. Review. No abstract available.

30.

Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5.

Le Gall M, Crépin R, Neiveyans M, Auclair C, Fan Y, Zhou Y, Marks JD, Pèlegrin A, Poul MA.

Mol Cancer Ther. 2015 Nov;14(11):2595-605. doi: 10.1158/1535-7163.MCT-15-0321. Epub 2015 Sep 10.

31.

Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.

Fan Y, Dong J, Lou J, Wen W, Conrad F, Geren IN, Garcia-Rodriguez C, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD.

Toxins (Basel). 2015 Aug 26;7(9):3405-23. doi: 10.3390/toxins7093405.

32.

Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou EY, Marks JD, Munro T, Mahler SM, Barnard RT, Fromm PD, Silveira PA, Elgundi Z, Ju X, Clark GJ, Bradstock KF, Munster DJ, Hart DN.

Leukemia. 2016 Mar;30(3):692-700. doi: 10.1038/leu.2015.231. Epub 2015 Aug 19.

PMID:
26286117
33.

Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity.

Fan Y, Geren IN, Dong J, Lou J, Wen W, Conrad F, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD.

PLoS One. 2015 Aug 14;10(8):e0135306. doi: 10.1371/journal.pone.0135306. eCollection 2015.

34.

TGF-β-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease.

Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Ma R, Murray LA, Tsui P, Lou J, Marks JD, Baron JL, Krummel MF, Nishimura SL.

J Immunol. 2015 Aug 1;195(3):1182-90. doi: 10.4049/jimmunol.1500348. Epub 2015 Jun 24.

35.

A fully human scFv phage display library for rapid antibody fragment reformatting.

Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks JD, Mallick P, Reiter RE, Wu AM.

Protein Eng Des Sel. 2015 Oct;28(10):307-16. doi: 10.1093/protein/gzv024. Epub 2015 May 19.

36.

Transforming Growth Factor-β and Interleukin-1β Signaling Pathways Converge on the Chemokine CCL20 Promoter.

Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, Nishimura SL.

J Biol Chem. 2015 Jun 5;290(23):14717-28. doi: 10.1074/jbc.M114.630368. Epub 2015 Apr 27.

37.

Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.

D'Souza JW, Reddy S, Goldsmith LE, Shchaveleva I, Marks JD, Litwin S, Robinson MK.

PLoS One. 2014 Nov 11;9(11):e112376. doi: 10.1371/journal.pone.0112376. eCollection 2014.

38.

High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display.

Zhao L, Qu L, Zhou J, Sun Z, Zou H, Chen YY, Marks JD, Zhou Y.

PLoS One. 2014 Oct 29;9(10):e111339. doi: 10.1371/journal.pone.0111339. eCollection 2014.

39.
40.

Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments.

Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM.

Mol Cancer Ther. 2014 Nov;13(11):2607-17. doi: 10.1158/1535-7163.MCT-14-0363. Epub 2014 Aug 20.

41.

Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins.

Jenko KL, Zhang Y, Kostenko Y, Fan Y, Garcia-Rodriguez C, Lou J, Marks JD, Varnum SM.

Analyst. 2014 Oct 21;139(20):5093-102. doi: 10.1039/c4an01270d. Epub 2014 Aug 12.

42.

Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation.

Tavaré R, Wu WH, Zettlitz KA, Salazar FB, McCabe KE, Marks JD, Wu AM.

Protein Eng Des Sel. 2014 Oct;27(10):317-24. doi: 10.1093/protein/gzu030. Epub 2014 Aug 4.

43.

Selective targeting of TGF-β activation to treat fibroinflammatory airway disease.

Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL.

Sci Transl Med. 2014 Jun 18;6(241):241ra79. doi: 10.1126/scitranslmed.3008074.

44.

Identifying blood-brain-barrier selective single-chain antibody fragments.

Jones AR, Stutz CC, Zhou Y, Marks JD, Shusta EV.

Biotechnol J. 2014 May;9(5):664-74. doi: 10.1002/biot.201300550. Epub 2014 Mar 18.

45.

Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A.

Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks JD, Binz T, Rummel A.

FEBS Lett. 2014 Apr 2;588(7):1087-93. doi: 10.1016/j.febslet.2014.02.034. Epub 2014 Feb 25.

46.

RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin.

Janardhanan P, Mello CM, Singh BR, Lou J, Marks JD, Cai S.

Talanta. 2013 Dec 15;117:273-80. doi: 10.1016/j.talanta.2013.09.012. Epub 2013 Sep 13.

47.

Sirtuin 3 deficiency does not augment hypoxia-induced pulmonary hypertension.

Waypa GB, Osborne SW, Marks JD, Berkelhamer SK, Kondapalli J, Schumacker PT.

Am J Respir Cell Mol Biol. 2013 Dec;49(6):885-91. doi: 10.1165/rcmb.2013-0191OC.

48.

Peroxiredoxin-5 targeted to the mitochondrial intermembrane space attenuates hypoxia-induced reactive oxygen species signalling.

Sabharwal SS, Waypa GB, Marks JD, Schumacker PT.

Biochem J. 2013 Dec 15;456(3):337-46. doi: 10.1042/BJ20130740.

49.
50.

Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E.

Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks JD, Rummel A, Binz T.

Biochem J. 2013 Jul 1;453(1):37-47. doi: 10.1042/BJ20130391.

PMID:
23621114

Supplemental Content

Loading ...
Support Center